Red Arrow Therapeutics Inc. closes $4.5M seed extension round

Red Arrow Therapeutics Inc. closed a $4.5M seed extension round, raising from four, top-tier institutional investors in Japan.

Participants of this round are:

• Beyond Next Ventures Inc.
• The University of Tokyo Edge Capital Partners Co., Ltd.
• Keio Innovation Initiative, Inc.
• OSAKA University Venture Capital Co., Ltd.

This boosts the accumulative funding raised by Red Arrow Therapeutics to nearly $5.5M, along with previous funding from The University of Tokyo Edge Capital Partners Co., Ltd., University of California, Berkeley’s accelerator SkyDeck , and other non-dilutive funding.

Emerging from the University of Tokyo’s Cabral Lab in 2021, Red Arrow Therapeutics Inc. develops pH-sensing nanomedicine drug delivery technologies for multiple therapeutic areas such as oncology. Headquartered in Boston, Massachusetts, the company is committed to delivering cutting-edge technology for patients in need worldwide.

The Seed extension round will allow Red Arrow Therapeutics to obtain key preclinical data on safety and efficacy of their lead compound, IL-12-loaded nanopolymeric micelles. The funding will also enable manufacturing initiation in collaboration with external partners.
MB Bureau